Your browser is no longer supported. Please, upgrade your browser.
Settings
STML Stemline Therapeutics, Inc. daily Stock Chart
STML [NASD]
Stemline Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.00 Insider Own10.50% Shs Outstand30.61M Perf Week-2.45%
Market Cap317.12M Forward P/E- EPS next Y-1.64 Insider Trans-0.81% Shs Float27.68M Perf Month-8.88%
Income-80.10M PEG- EPS next Q-0.73 Inst Own64.40% Short Float5.62% Perf Quarter-39.85%
Sales0.50M P/S634.24 EPS this Y-36.70% Inst Trans-2.55% Short Ratio5.39 Perf Half Y-41.63%
Book/sh2.19 P/B4.73 EPS next Y41.60% ROA-90.20% Target Price28.50 Perf Year-29.76%
Cash/sh2.57 P/C4.03 EPS next 5Y- ROE-114.50% 52W Range9.65 - 20.55 Perf YTD-33.59%
Dividend- P/FCF- EPS past 5Y-10.00% ROI-145.60% 52W High-49.59% Beta0.72
Dividend %- Quick Ratio4.60 Sales past 5Y- Gross Margin- 52W Low7.36% ATR0.85
Employees80 Current Ratio4.60 Sales Q/Q- Oper. Margin- RSI (14)40.71 Volatility8.15% 7.80%
OptionableYes Debt/Eq0.00 EPS Q/Q-6.00% Profit Margin- Rel Volume1.71 Prev Close10.74
ShortableYes LT Debt/Eq0.00 EarningsNov 08 Payout- Avg Volume288.30K Price10.36
Recom1.70 SMA20-3.60% SMA50-22.05% SMA200-34.92% Volume493,007 Change-3.54%
Dec-11-18Initiated JP Morgan Overweight $17
Nov-26-18Initiated Piper Jaffray Overweight $20
Jun-12-18Initiated ROTH Capital Buy $30
Nov-01-17Reiterated H.C. Wainwright Buy $34 → $38
Feb-06-17Reiterated Wedbush Outperform $19 → $11
Mar-15-16Reiterated Wedbush Outperform $19 → $15
Apr-27-15Initiated H.C. Wainwright Buy $38
Apr-22-15Resumed Jefferies Buy
Jan-26-15Reiterated ROTH Capital Buy $62 → $50
Oct-30-13Reiterated Aegis Capital Buy $40 → $70
Dec-07-18 01:29PM  Stemline Therapeutics (STML): Elzonris Approval Dawning on the Horizon, Says Analyst SmarterAnalyst
07:00AM  3 Biotech Stocks That Could Explode Higher in 2019 SmarterAnalyst
Dec-06-18 07:00AM  Stemline Therapeutics Recaps Key Clinical Data Presentations from the American Society of Hematology (ASH) Annual Meeting GlobeNewswire
Nov-30-18 07:00AM  Stemline Therapeutics Highlights Four ELZONRIS Presentations, Including an Oral Presentation, at the Upcoming ASH Meeting GlobeNewswire +8.60%
Nov-27-18 08:30AM  Report: Developing Opportunities within Koppers, Flowers Foods, Stemline Therapeutics, Aqua Metals, athenahealth, and Bojangles' Future Expectations, Projections Moving into 2018 GlobeNewswire -11.98%
Nov-21-18 02:59PM  What Kind Of Investor Owns Most Of Stemline Therapeutics Inc (NASDAQ:STML)? Simply Wall St. +11.40%
Nov-20-18 07:00AM  Stemline Therapeutics Announces that European Medicines Agency (EMA) Grants Accelerated Assessment for planned ELZONRIS Marketing Authorization Application (MAA) GlobeNewswire
Nov-16-18 07:30AM  Stemline Therapeutics Announces Oral Presentation of SL-701 Phase 2 Data in Second-Line Glioblastoma at the 23rd Annual Meeting of the Society of Neuro-Oncology (SNO) GlobeNewswire
Nov-08-18 05:17PM  Stemline Therapeutics: 3Q Earnings Snapshot Associated Press
04:01PM  Stemline Therapeutics Reports Third Quarter 2018 Financial Results GlobeNewswire
Nov-02-18 07:30AM  Stemline Therapeutics Announces Four ELZONRIS Presentations, Including an Oral Presentation, at Upcoming ASH Meeting GlobeNewswire
Oct-16-18 07:30AM  Stemline Therapeutics Announces SL-701 and SL-801 Clinical Data to be Featured, Including an Oral Presentation, at Upcoming ESMO 2018 Congress GlobeNewswire +6.21%
Oct-11-18 08:20AM  Consolidated Research: 2018 Summary Expectations for Casella Waste, ServiceNow, MKS Instruments, FirstEnergy, Stemline Therapeutics, and CMS Energy Fundamental Analysis, Key Performance Indications GlobeNewswire
Oct-09-18 05:50PM  Newman Ferrara LLP Announces Corporate Governance Investigation of Stemline Therapeutics Inc. - STML Business Wire
Sep-28-18 07:00AM  Stemline Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Sep-18-18 02:37PM  When Will Stemline Therapeutics Inc (NASDAQ:STML) Turn A Profit? Simply Wall St.
Sep-05-18 07:00AM  Stemline Therapeutics to Present at the H.C. Wainwright 20th Annual Global Investment Conference GlobeNewswire
Aug-14-18 07:30AM  Stemline Therapeutics to Present at the 2018 Wedbush PacGrow Healthcare Conference GlobeNewswire
Aug-13-18 09:25AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
06:30AM  Stemline Therapeutics Announces that FDA Accepts ELZONRIS Biologics License Application (BLA) and Grants Priority Review GlobeNewswire
Aug-09-18 08:18AM  Stemline Therapeutics: 2Q Earnings Snapshot Associated Press +5.63%
08:00AM  Stemline Therapeutics Reports Second Quarter 2018 Financial Results GlobeNewswire
Aug-06-18 07:55AM  Report: Developing Opportunities within Stemline Therapeutics, Silgan, CVR Energy, MINDBODY, FireEye, and Quality Future Expectations, Projections Moving into 2018 GlobeNewswire
Jun-25-18 07:00AM  Stemline Therapeutics Announces Completion of Rolling BLA Submission for ELZONRIS (tagraxofusp; SL-401) for the Treatment of BPDCN GlobeNewswire
Jun-19-18 10:00AM  Biotechnology Firm PPCB, Shows Great Potential ACCESSWIRE
Jun-18-18 07:00AM  Stemline Therapeutics Announces Positive Clinical Data from ELZONRISTM (tagraxofusp; SL-401) Trials in BPDCN, CMML and MF Delivered at the EHA Congress GlobeNewswire
Jun-15-18 08:15AM  Stemline Therapeutics Announces Presentation of ELZONRIS (tagraxofusp; SL-401) Preclinical Data in Systemic Sclerosis, an Autoimmune Disorder, at EULAR Congress GlobeNewswire
Jun-14-18 07:00AM  Stemline Therapeutics Announces Three ELZONRIS (tagraxofusp; SL-401) Clinical Presentations, Including an Oral Presentation, at the EHA Congress GlobeNewswire
Jun-05-18 07:00AM  Stemline Therapeutics Announces Positive Data Presentations on SL-701 and SL-801 at ASCO GlobeNewswire
May-22-18 07:20AM  Wired News - Stemline Therapeutics' SL-401 BPDCN Program Selected for Clinical Presentations at Upcoming EHA Congress ACCESSWIRE
May-18-18 07:00AM  Stemline Therapeutics Announces Three SL-401 Clinical Presentations, Including an Oral Presentation, at the Upcoming EHA Congress GlobeNewswire
May-17-18 07:00AM  Stemline Therapeutics Announces Presentation of SL-801 and SL-701 Clinical Data at the Upcoming ASCO Annual Meeting GlobeNewswire
May-09-18 04:26PM  Stemline Therapeutics: 1Q Earnings Snapshot Associated Press
04:00PM  Stemline Therapeutics Reports First Quarter 2018 Financial Results GlobeNewswire
May-02-18 06:04PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Stemline Therapeutics, Inc. Business Wire
May-01-18 01:43PM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Stemline Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
Apr-30-18 08:25AM  Report: Exploring Fundamental Drivers Behind Agilysys, Editas Medicine, The ExOne, Central Garden & Pet, Quality, and Stemline Therapeutics New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Apr-26-18 07:00AM  Stemline Therapeutics Announces Clinical Presentations of SL-801 and SL-701 at the Upcoming ASCO Annual Meeting GlobeNewswire
Apr-16-18 07:00AM  Stemline Therapeutics Expands Board of Directors; Further Enhances Commercial Expertise with Appointment of Darren Cline GlobeNewswire
Apr-09-18 07:10AM  Wired News Stemline Therapeutics Initiates Rolling BLA Submission for SL-401 ACCESSWIRE +7.28%
Apr-05-18 07:00AM  Stemline Therapeutics Announces Start of Rolling BLA Submission for SL-401 GlobeNewswire
Mar-19-18 07:50AM  Report: Exploring Fundamental Drivers Behind Fluidigm, Acuity Brands, TTEC, Actuant, Equity Lifestyle Properties, and Stemline Therapeutics New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
07:30AM  Stemline Therapeutics to Present at the Oppenheimer 28th Annual Healthcare Conference GlobeNewswire
Mar-16-18 08:05AM  Stemline Therapeutics reports 4Q loss Associated Press -6.33%
07:30AM  Stemline Therapeutics Reports Fourth Quarter 2017 Financial Results GlobeNewswire
Mar-14-18 07:34AM  Breakeven On The Horizon For Stemline Therapeutics Inc (NASDAQ:STML) Simply Wall St.
Mar-08-18 07:30AM  Stemline Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Jan-30-18 11:02AM  Top 3 Growth Stocks For The Month Simply Wall St.
Jan-26-18 10:21AM  Stemline Therapeutics Closes $59.6 Million Public Offering of Common Stock GlobeNewswire +6.41%
Jan-24-18 07:00AM  Stemline Therapeutics Prices $51.8 Million Public Offering of Common Stock GlobeNewswire +7.77%
Jan-22-18 04:01PM  Stemline Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire +5.17%
Jan-09-18 07:30AM  Detailed Research: Economic Perspectives on Fluidigm, Stemline Therapeutics, NeoGenomics, CVR Energy, W.R. Berkley, and Mack-Cali Realty What Drives Growth in Today's Competitive Landscape GlobeNewswire
Jan-08-18 02:24PM  Newman Ferrara LLP Announces Corporate Governance Investigation of Stemline Therapeutics Inc. - STML Business Wire -5.12%
Jan-04-18 08:00AM  Stemline Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire -5.00%
Dec-26-17 12:11PM  ETFs with exposure to Stemline Therapeutics, Inc. : December 26, 2017 Capital Cube
Dec-25-17 11:02AM  Best-In-Class Growth Stocks Simply Wall St.
09:26AM  Stemline Therapeutics, Inc. :STML-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017 Capital Cube
Dec-13-17 08:47AM  Stemline Therapeutics shares jump 4% premarket after positive trial of leukemia treatment MarketWatch
08:36AM  Stemline Therapeutics Presents Detailed SL-401 Pivotal Data in BPDCN at ASH and Kicks Off its BPDCN Awareness Campaign; Updated Results From Ongoing Trials in Additional Malignancies Also Presented GlobeNewswire
Dec-08-17 07:00AM  Stemline Therapeutics Announces Four SL-401 Presentations at Upcoming ASH Meeting GlobeNewswire
Nov-16-17 07:00AM  Stemline Therapeutics Announces Oral Presentation of SL-701 Phase 2 Data in Second-Line Glioblastoma at the 22nd Annual Meeting of the Society of Neuro-Oncology (SNO) GlobeNewswire
Nov-09-17 05:14PM  Stemline Therapeutics reports 3Q loss Associated Press
04:01PM  Stemline Therapeutics Reports Third Quarter 2017 Financial Results GlobeNewswire
Nov-06-17 12:29PM  Here's Why Stemline Therapeutics Inc. Jumped 23% Higher in October Motley Fool -6.01%
Nov-04-17 03:02PM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Nov-02-17 12:35PM  ETFs with exposure to Stemline Therapeutics, Inc. : November 2, 2017 Capital Cube
Nov-01-17 09:02AM  Stemline Announces Four SL-401 Presentations at Upcoming ASH Meeting GlobeNewswire
Oct-31-17 04:21PM  The Clear Reason Why Stemline Therapeutics Inc. Skyrocketed as Much as 33% Motley Fool +29.38%
12:02PM  Growth Stocks Investors Love Simply Wall St.
07:00AM  Stemline Therapeutics Announces that Pivotal Trial of SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Meets Primary Endpoint GlobeNewswire
Sep-20-17 07:00AM  Stemline Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Sep-11-17 07:00AM  Stemline Therapeutics Presents SL-801 Phase 1 Data at ESMO 2017 GlobeNewswire
Sep-08-17 07:30AM  Stemline Therapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment Conference GlobeNewswire
Aug-31-17 09:14PM  ETFs with exposure to Stemline Therapeutics, Inc. : September 1, 2017 Capital Cube
Aug-30-17 06:10PM  Stemline Therapeutics to Present SL-801 Phase 1 Data at Upcoming ESMO Congress GlobeNewswire
Aug-24-17 10:51AM  Stemline Therapeutics, Inc. :STML-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 Capital Cube
Aug-14-17 07:30AM  Stemline Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference GlobeNewswire
Aug-08-17 05:48PM  Stemline Therapeutics reports 2Q loss Associated Press
07:00AM  Stemline Therapeutics Reports Second Quarter 2017 Financial Results GlobeNewswire
Jun-23-17 09:36AM  Stemline Therapeutics Presents SL-401 Updated Stage 1 and 2 Data from Ongoing Pivotal Trial in BPDCN and Safety Experience Across Multiple Indications, Today at EHA GlobeNewswire +7.06%
Jun-06-17 07:30AM  Stemline Therapeutics to Present at the Jefferies 2017 Healthcare Conference GlobeNewswire
May-31-17 08:50AM  Implied Volatility Surging for Stemline Therapeutics (STML) Stock Options Zacks
May-18-17 07:30AM  Stemline Therapeutics to Present SL-401 Updated Data from Stage 1 and 2 of Ongoing Pivotal Phase 2 BPDCN Trial at Upcoming European Hematology Association (EHA) Meeting GlobeNewswire
May-16-17 01:12PM  Newman Ferrara LLP Announces Corporate Governance Investigation of Stemline Therapeutics Inc. Business Wire
May-10-17 05:38PM  Stemline Therapeutics reports 1Q loss Associated Press
05:13PM  Stemline Therapeutics Reports First Quarter 2017 Financial Results GlobeNewswire
May-02-17 08:30PM  J&W Investigates Investment Technology Group (ITG) and Stemline Therapeutics (STML); Should Officers and Directors be Responsible for Alleged Harm to the Company? PR Newswire
May-01-17 07:00AM  Stemline Therapeutics to Present at the Deutsche Bank 42nd Annual Health Care Conference GlobeNewswire
Apr-03-17 10:55AM  DEADLINE TOMORROW: Lundin Law PC Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Reminds Investors with Losses to Contact the Firm Accesswire
10:41AM  FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Stemline Therapeutics, Inc. (STML) and Lead Plaintiff Deadline: April 4, 2017 Accesswire
10:32AM  DEADLINE TOMORROW: Levi & Korsinsky, LLP Reminds Shareholders it Filed a Complaint to Recover Losses Suffered by Investors in Stemline Therapeutics, Inc. - Lead Plaintiff Deadline of April 4, 2017 - STML Accesswire
Mar-31-17 10:50PM  STEMLINE 96 HOUR DEADLINE ALERT: APPROXIMATELY 96 HOURS REMAIN; FORMER LOUISIANA ATTORNEY GENERAL AND KAHN SWICK & FOTI, LLC REMIND INVESTORS of Deadline in Class Action Lawsuit Against Stemline Therapeutics, Inc. (STML) GlobeNewswire
12:10PM  UPCOMING DEADLINE ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Reminds Investors with Losses to Contact the Firm GlobeNewswire
11:27AM  STML UPCOMING DEADLINE: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Stemline Therapeutics, Inc. and a Lead Plaintiff Deadline of April 4, 2017 GlobeNewswire
11:09AM  DEADLINE TUESDAY: Lundin Law PC Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
10:30AM  April 4 Deadline Alert: Law Offices of Howard G. Smith Reminds Stemline Therapeutics, Inc. Investors of Upcoming Lead Plaintiff Deadline Business Wire
Mar-30-17 09:52PM  APRIL 4 DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm GlobeNewswire
08:53PM  Deadline Alert: GPM Reminds Investors of the April 4 Deadline in the Class Action Lawsuit Against Stemline Therapeutics, Inc. Business Wire
11:39AM  DEADLINE APPROACHING: Lundin Law PC Announces Securities Class Action Lawsuit against Stemline Therapeutics, Inc. and Reminds Investors with Losses to Contact the Firm Accesswire
10:10AM  DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Stemline Therapeutics, Inc. (STML) & Lead Plaintiff Deadline: April 4, 2017 GlobeNewswire
Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma. It also develops SL-801, a novel oral small molecule reversible inhibitor of nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that has completed Phase II clinical trial to attack brain cancer. The company's preclinical pipeline products include SL-501, a next generation IL-3R-targeted therapy; SL-101, a single chain monoclonal antibody fragment for the treatment of hematologic cancers; and SL-901, a small molecule kinase inhibitor. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hoberman KennethChief Operating OfficerNov 26Sale11.8526,296311,608659,738Nov 30 08:59 PM
Hoberman KennethChief Operating OfficerMar 13Sale16.8212,746214,388409,594Mar 14 09:30 PM
Hoberman KennethChief Operating OfficerMar 12Sale17.3817,241299,697422,340Mar 14 09:30 PM
Gionco DavidChief Accounting OfficerMar 12Sale17.389,183159,595180,684Mar 14 09:30 PM
Bergstein IvanChief Executive OfficerMar 12Sale17.3437,857656,4392,156,431Mar 14 09:30 PM
Gionco DavidChief Accounting OfficerMar 07Sale16.561,41323,399152,275Mar 09 09:31 PM
Hoberman KennethChief Operating OfficerMar 07Sale16.553,02750,097369,278Mar 09 09:32 PM
Bergstein IvanChief Executive OfficerMar 07Sale16.566,797112,5582,050,580Mar 09 09:31 PM
Bergstein IvanChief Executive OfficerFeb 27Sale17.2613,407231,4052,057,377Feb 28 09:32 PM
Gionco DavidChief Accounting OfficerFeb 27Sale17.264,58479,120153,554Feb 28 09:32 PM
Hoberman KennethChief Operating OfficerFeb 27Sale17.265,72698,831371,915Feb 28 09:31 PM
Bergstein IvanChief Executive OfficerFeb 26Sale17.6110,776189,7652,070,784Feb 28 09:32 PM
Gionco DavidChief Accounting OfficerFeb 26Sale17.614,40077,484158,138Feb 28 09:32 PM
Hoberman KennethChief Operating OfficerFeb 26Sale17.615,30093,333377,641Feb 28 09:31 PM
Bergstein IvanChief Executive OfficerFeb 15Sale15.803,82060,3562,081,560Feb 16 09:31 PM
Hoberman KennethChief Operating OfficerFeb 15Sale15.671,85129,005382,941Feb 16 09:31 PM
Gionco DavidChief Accounting OfficerJan 17Sale13.434,25057,078162,538Jan 19 09:30 PM
Hoberman KennethChief Operating OfficerJan 08Sale13.9314,040195,577384,792Jan 12 09:31 PM